Cover Image

JNK inhibitors: is there a future?

Jonas Cicenas
  • Jonas Cicenas
    MAP Kinase Resource and Institute of Animal Pathology, Bern, Switzerland; Vetsuisse Faculty, University of Bern and Proteomics Centre, Bern, Switzerland; Institute of Biochemistry, Vilnius University, Lithuania | j.cicenas@mapkinases.eu

Abstract

JNK is a subfamily of MAP kinases that hat regulates a range of biological processes implicated in response to stress, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock as well as growth factors like PDGF, EGF, FGF, etc. They were originally identified as kinases that bind and phosphorylate JUN on S63 and Se73 within its transcriptional activation domain. The deregulation of these kinases is shown to be involved in human diseases, such as cancer, immune diseases and neurodegenerative disorders. The realization of the therapeutic potential of the inhibition of JNKs led to a thorough search for small-molecule inhibitors first for research purposes, but later also for therapeutic applications. Here, we discuss some of the most well-known JNK inhibitors and their use in basic research or clinical science.

Keywords

JNK inhibitors; editorial.

Full Text:

PDF
Submitted: 2015-12-20 11:03:56
Published: 2015-12-28 18:21:14
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
983

Views:
PDF
717

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2015 Jonas Cicenas

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185